Abstract: A computer receives a first audio signal that is acquired by a first user device used by a first user in a conference and a second audio signal that is acquired by a second user device used by a second user in the conference. The computer processes the first audio signal based on the second audio signal to improve quality of the first audio signal, and sends the processed first audio signal to the conference.

Abstract: Contact structures and methods of forming contacts structures are contemplated by this disclosure. A structure includes a dielectric layer over a substrate, an adhesion layer, a silicide, a barrier layer, and a conductive material. The dielectric layer has an opening to a surface of the substrate. The adhesion layer is along sidewalls of the opening. The silicide is on the surface of the substrate. The barrier layer is on the adhesion layer and the silicide, and the barrier layer directly adjoins the silicide. The conductive material is on the barrier layer in the opening.

Abstract: Contact structures and methods of forming contacts structures are contemplated by this disclosure. A structure includes a dielectric layer over a substrate, an adhesion layer, a silicide, a barrier layer, and a conductive material. The dielectric layer has an opening to a surface of the substrate. The adhesion layer is along sidewalls of the opening. The silicide is on the surface of the substrate. The barrier layer is on the adhesion layer and the silicide, and the barrier layer directly adjoins the silicide. The conductive material is on the barrier layer in the opening.

Abstract: Provided is a method for regulation of lipid metabolism comprising a step of administering to a subject in need thereof a therapeutically amount of pharmaceuticals. The pharmaceuticals comprise an effective amount of a composition containing a ferrous amino acid chelate and pharmaceutically acceptable carriers to regulate lipid metabolism. The amino acid is capable of being chelated with the ferrous iron in a chelated state stably as passing through a stomach. The composition containing the ferrous amino acid chelate can effectively control the variances of body weight and enhance metabolism of body fat of a subject. The pharmaceuticals prepared by the composition containing the ferrous amino acid chelate have effects on regulation of lipid metabolism.

Abstract: An interconnect structure and a method of forming an interconnect structure are disclosed. The interconnect structure includes a contact layer over a substrate, a dielectric layer over the contact layer, a silicide layer over the exposed portion of the contact layer, a barrier layer along sidewalls of the opening, an alloy layer over the barrier layer, a glue layer over the alloy layer, and a conductive plug over the glue layer, wherein the dielectric layer has an opening, and the opening exposes a portion of the contact layer.

Abstract: The present invention provides a use of a composition containing a ferrous amino acid chelate for the preparation of a pharmaceutical used in diabetes improvement. The pharmaceutical comprise an effective amount of the composition containing the ferrous amino acid chelate and pharmaceutically acceptable carriers to improve diabetes. The amino acid is able to be chelated with the ferrous iron in a chelated state stably as passing through the stomach. The composition containing the ferrous amino acid chelate can effectively lower blood glucose and improve insulin sensitivity. The pharmaceutical prepared by the composition containing the ferrous amino acid chelate have effect on diabetes improvement.

Abstract: A computer receives a first audio signal that is acquired by a first user device used by a first user in a conference and a second audio signal that is acquired by a second user device used by a second user in the conference. The computer processes the first audio signal based on the second audio signal to improve quality of the first audio signal, and sends the processed first audio signal to the conference.

Abstract: An interconnect structure and a method of forming an interconnect structure are disclosed. The interconnect structure includes a contact layer over a substrate, a dielectric layer over the contact layer, a silicide layer over the exposed portion of the contact layer, a barrier layer along sidewalls of the opening, an alloy layer over the barrier layer, a glue layer over the alloy layer, and a conductive plug over the glue layer, wherein the dielectric layer has an opening, and the opening exposes a portion of the contact layer.

Abstract: The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing acardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.

Abstract: An interconnect structure and a method of forming an interconnect structure are disclosed. The interconnect structure includes a contact layer over a substrate; a dielectric layer over the contact layer, wherein the dielectric layer has an opening, the opening exposing a portion of the contact layer; a silicide layer over the exposed portion of the contact layer; a barrier layer along sidewalls of the opening; an alloy layer over the barrier layer; a glue layer over the alloy layer; and a conductive plug over the glue layer.

Abstract: An interconnect structure and a method of forming an interconnect structure are disclosed. The interconnect structure includes a contact layer over a substrate; a dielectric layer over the contact layer, wherein the dielectric layer has an opening, the opening exposing a portion of the contact layer; a silicide layer over the exposed portion of the contact layer; a barrier layer along sidewalls of the opening; an alloy layer over the barrier layer; a glue layer over the alloy layer; and a conductive plug over the glue layer.

Abstract: Contact structures and methods of forming contacts structures are contemplated by this disclosure. A structure includes a dielectric layer over a substrate, an adhesion layer, a silicide, a barrier layer, and a conductive material. The dielectric layer has an opening to a surface of the substrate. The adhesion layer is along sidewalls of the opening. The silicide is on the surface of the substrate. The barrier layer is on the adhesion layer and the silicide, and the barrier layer directly adjoins the silicide. The conductive material is on the barrier layer in the opening.

Abstract: A multi-touch method includes, in response to at least one finger of a user pointing toward a computer screen, recognizing an eye and at least one finger in an image frame taken by a camera; mapping a first coordinate of the recognized finger in the image frame to a second coordinate of the finger on the computer screen; mapping a third coordinate the recognized eye in the image frame to a fourth coordinate of the eye on the computer screen; determining whether the fourth coordinate is in the proximity of the second coordinate; in response to a positive decision, determining the second coordinate as a multi-touch point.

Abstract: The present invention is related to a method for cancer treatment comprising a step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ferrous amino acid chelate and a pharmaceutically acceptable carrier. By means of amino acid chelating to ferrous and maintaining chelating state through the stomach, the pharmaceutical composition in accordance with the present invention would not cause any weight variation, and is suitable for inhibiting or treating cancer.

Abstract: The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.

Abstract: Disclosed are dihydroindolone compounds which can modulate the activity of protein tyrosine kinases, a method for preparing the same, and pharmaceutical compositions comprising the same. Also disclosed are use of such compounds and pharmaceutical compositions thereof in the treatment and/or prophylaxis of protein tyrosine kinase associated diseases in an organism, particularly in the treatment and/or prophylaxis of tumors and fibroblast proliferation associated diseases.

Abstract: A heat dissipating device supporting apparatus includes a base, and a securing element mounted to the mounting portion. The base includes a main body configured to support a heat dissipating device and a mounting portion extending from the main body. The securing element includes a fastener, an elastic member, and a mounting member. The mounting member includes a cavity portion, a supporting portion extending from the cavity portion, and a protrusion extending from an inner side the cavity portion. The supporting portion defines a through hole. The fastener includes a head portion and a shaft portion extending from the head portion. A cross-section of the head portion is greater than that of the shaft portion. The shaft portion is located in the through hole. The elastic member resists resiliently between the head portion and the supporting portion. The head portion resists between the elastic member and the protrusion.

Abstract: The invention provides a composition for inhibiting proline-directed protein kinase FA/glycogen synthase kinase 3? (PDPK FA/GSK-3?), experiments verified that the composition can effectively inhibit the PDPK FA/GSK-3?. In addition, inhibition of PDPK FA/GSK-3? can improve the clinical efficacy of cancer treatment and cure rate.

Abstract: A pseudo dual-port memory device is disclosed. One embodiment provides an internal data RAM for a microprocessor, and a method for operating a memory device. In one embodiment, a memory device for a microprocessor or microcontroller comprises: a first part with memory cells that are single-port memory cells; and a second part with memory cells that are dual-port memory cells. In another embodiment, a method for operating a memory device is provided, the memory device including at least one single-port memory and at least one dual-port memory, the method including: accessing the single-port memory of the memory device when a non-conflicting access is to be carried out at the memory device; and accessing the dual-port memory of the memory device when a conflicting access is to be carried out at the memory device.